Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia

Xin-guang Liu; Ming Hou

doi:10.1515/med-2016-0019

Artikel Open Access

Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia

Xin-guang Liu und Ming Hou

Veröffentlicht/Copyright: 18. April 2016

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Open Medicine Band 11 Heft 1

Abstract

Primary immune thrombocytopenia (ITP) is a complex autoimmune disorder in which the patient’s immune system reacts with platelet autoantigens resulting in immune-mediated platelet destruction and/or suppression of platelet production. Corticosteroids can induce sustained remission rates in 50% to 75% of patients with active ITP. For these patients who are unresponsive to glucocorticoids, or relapsed after an initial response, multiple second-line treatment modalities can be chosen. However, how to make an optimal therapeutic strategy for a specific patient still remains a major challenge. As the pathogenetic heterogeneity of the ITP is increasingly identified, pathogenesis-oriented approach might offer an opportunity to improve the outcome of corticosteroid-resistant or relapsed ITP.

Keywords: ITP; Pathogenesis; Management

1 Introduction

Primary immune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by transient or persistent decrease of the platelet count (peripheral blood platelet count < 100 × 10⁹/L) in the absence of conditions known to cause thrombocytopenia, and increased risk of bleeding depending on the degree of thrombocytopenia [1]. According to population-based studies, the overall incidence of ITP ranges from 3.2 – 12.1 per 10⁵ adults each year [2-4], and recent epidemiologic data suggest nearly equal incidence for both sexes, except in women of childbearing age, when the disease is more prevalent in female [2]. ITP in adults typically has an insidious onset which is usually followed by a chronic course. Manifestations of ITP are very heterogeneous. A large proportion of patients have either no symptoms or minimal bruising, while others may exhibit severe bleeding, such as intracranial hemorrhage (ICH), gastrointestinal hemorrhage (GI), or extensive skin and mucosal hemorrhage. Besides the level of platelet counts, additional factors (life style, age, uremia, etc) affect the risk of bleeding in ITP.

Historically, ITP has been thought as an autoantibody-mediated hemorrhagic disease involving increased platelet destruction by macrophages in the reticuloendothelial system [5]. Aside from humoral immune abnormalities, T-cell-mediated immunity also plays important roles in platelet destruction. Antiplatelet autoantibody production is under the control of platelet-specific T helper (Th) cells, and loss of tolerance to self antigen by T cells is the critical step of the immune dysregulation in ITP [6,7]. Antiplatelet T-cell reactivity in ITP patients has been shown to be enhanced at polyclonal and oligoclonal levels [8-11]. Defects of the apoptotic pathway in T cells could promote the survival of autoreactive T cells in ITP. Additionally, T-cell subset polarization in ITP has been attributed to increased Th1 [12,13], Th17 [14], Th22 cells [15,16] and reduced number or function of CD4⁺CD25⁺Foxp3⁺ T-regulatory cells (Tregs) [17,18]. CD8⁺ cytotoxic T lymphocyte (CTL)-mediated platelet lysis or apoptosis is another mechanism of platelet destruction [19,20], especially in patients with negative glycoptotein (GP)-specific autoantibodies [21]. Besides the accelerated platelet clearance, the decreased platelet production has been recently identified as an important mechanism contributing to thrombocytopenia in ITP. Autoantibodies may impair megakaryocyte development and maturation, induce apoptosis-like programmed megakaryocyte death, and impede platelet release. CTLs in bone marrow of ITP have also been reported to impair platelet production via suppression megakaryocyte apoptosis.

Glucocorticoids, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin (anti-D) are traditional first-line therapy for ITP and most patients achieve a durable response. For patients who fail first-line therapy, splenectomy or second-line drugs such as Rituximab, thrombopoietin-receptor agonists (TPO-RAs) and immunosuppressive agents can be chosen. Management of ITP is dependent on multiple factors such as platelet count, bleeding symptoms, patient age, health-related quality of life, and side effects associated with therapy [22]. Moreover, patients’ perspective, anticipated response rates, comorbidities, and compliance should be taken into account when making treatment plans.

2 Highlights

Treatment of ITP should always be tailored to the individual patients, and novel pathogenesis-oriented approaches might be potential for the management of corticosteroid-resistance or relapsed ITP.

3 Discussion

Recent years have witnessed major progress in the management of ITP as several novel agents have been developed. Based on the mechanism of action, available second-line treatment modalities for ITP can be broadly classified into those that target to decrease the destruction of platelets, and those that aim to increase the production of platelets. The major site of platelet destruction is spleen in which autoantibody-opsonized platelets are phagocytosed by macrophagesin aFcγ receptor (Fcγ)-dependent manner. FcγR blocking treatment with IVIG has been used for a long time. Our group recently found that the efficacy of IVIG or dexamethasone in ITP was associated with autoantibody species, and GPIbα-autoantibody-positive patients were demonstrated to be less responsive to IVIG or dexamethasone therapy comparing with GPIbα-autoantibodynegative patients [23,24]. Splenectomy removes both the mechanism of platelet destruction and a large source of autoantibody production. Standard medical treatment modalities that aim to decrease platelet destruction in ITP include a variety of immunosuppressive or immunoregulatory agents. For instance, B-cell depletion therapy with rituximab has been successful used in inducing remission of ITP [25,26]. Other immunosuppressant, such as cyclosporine A (CsA), cyclophosphamide (CTX), azathioprine, mycophenolatemofetil (MMF), and vinca alkaloids have been shown to be clinical effective in ITP management. Rather than modulating the immune system, another therapeutic approach is to stimulate platelet production. TPO is the primary factor regulating platelet production. Along these lines, the TPO-RAs, eltrombopag [27,28], romiplostim [29,30], and recombinant human thrombopoietin (rhTPO) launched in China [31], have been shown to be effective, with comparatively high response and low toxicity. Before administering these drugs, possible side effects and methods of administration should be considered to ensure a safe environment for drug use.

ITP is a very heterogeneous condition and it is unlikely that a single pathogenetic mechanism underlies all cases. Experimental treatment using combination therapy with different drugs targeting diverse mechanisms of action has yielded encouraging outcomes. Two groups recently reported identically that dexamethasone plus rituximab could induce higher response rates and longer time to relapse than dexamethasone monotherapy, with non-overlapping toxicities in previously untreated adult ITP [32,33]. However, compared with dexamethasone monotherapy, dexamethasone plus rituximab therapy showed increased incidences of grade 3 to 4 adverse events (AEs), including pneumonia, fever, transaminase increase, et al [32,33]. In order to reduce serious AEs, combination therapy should avoid overlapping toxicities of drugs as much as possible. rhTPO in combination with CsA was reported to be effective for the management of corticosteroid-resistant ITP, with a relative short time to response and low recurrence rate [34]. Our recently published results from a multicenter clinical trial showed that the combination therapy with rituximab and rhTPO which targeted both increased platelet destruction and insufficient platelet production, could overcome the long time to response (TTR) of rituximab and short duration of response of rhTPO, thus yielded a shorter TTR and a longer time to relapse compared with rituximab monotherapy in the treatment of corticosteroid-resistant or relapsed ITP [35]. A triple-therapy regimens combining romiplostim with CsA and IVIG were demonstrated to be effective to manage patients with refractory ITP. These 3 agents target different mechanisms of ITP pathobiology: inhibition of T cell activation (CsA), stimulation of platelet production (romiplostim), and FcγR blockade (IVIg), and were well tolerated in most patients [36]. Nevertheless, it is notable that the abstract presented by Leven E, et al. at the 54th ASH annual meeting was a retrospective study, and only 9 patients were included. Furthermore, dosages of CsA, IVIg and romiplostim in the study were individually adjusted, lacking a unified criterion [36], and further perspective studies are needed to evaluate the effectiveness and safety of the therapeutic modality [36]. Recently, our group showed that exogenous rhBAFF could not only promote the survival of CD19+ B cells and CD8+ T cells, but also increase the apoptosis of platelets in vitro. Moreover, it is noteworthy that effect of rhBAFF could be neutralized by BAFF-R-Fc fusion protein (BR3-Fc) [37]. Considering the crucial role of elevated B-cell activating factor (BAFF) in the maintenance of autoreactive B-cell development [37-40], blockade of BAFF signaling with BAFF-receptor-Fc fusion protein (BR3-Fc) or belimumab might be potential in ITP treatment [40,41]. In line with that, rituximab in combination with BAFF inhibitors might be a novel promising therapeutic strategy for ITP management as additional BAFF blockade could antagonize the strengthened BAFF signaling which was a feedback of B-cell loss induced by rituximab. Further clinical trials are needed to evaluate the effect of those novel therapeutic modalities in ITP.

During the past few years, a growing body of emerging evidence has advanced our appreciation of the pathophysiology of ITP and improved our understanding of the heterogeneity of the disease. Further exploration of the pathogenesis of ITP would help to identify disease features and predictors of treatment response, thus facilitating the decision-making process for ITP management. Taking together, the potential mechanisms of ITP are multiple, and novel pathogenesis-oriented approaches could act as potential therapeutics for the treatment of corticosteroid-resistant or relapsed ITP.

Acknowledgements

This work was supported by grants from Independent Innovation Foundation of Shandong University (No. 2012TS134), National Natural Science Foundation of China (No.81200344, 81570103).

Conflict of interest statement: Authors state no conflict of interest.
Author’s Contribution: Xin-guang Liu proposed the idea, reviewed recent literature, and wrote the manuscript. Ming Hourevisedthe manuscript critically for important intellectual content.

References

1 Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-239310.1182/blood-2008-07-162503Suche in Google Scholar PubMed

2 Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377-238310.1111/j.1538-7836.2006.02147.xSuche in Google Scholar PubMed

3 Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010;85:174-18010.1002/ajh.21616Suche in Google Scholar PubMed

4 Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol 2012;87:848-85210.1002/ajh.23262Suche in Google Scholar PubMed PubMed Central

5 Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993;81:1246-125010.1182/blood.V81.5.1246.1246Suche in Google Scholar

6 Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 2012;19:357-36210.1097/MOH.0b013e3283567541Suche in Google Scholar PubMed

7 Liu XG, Peng J, Hou M. Restoration of T cell tolerance in primary ITP. J Hematol Oncol 2012;5(Suppl):A510.1186/1756-8722-5-S1-A5Suche in Google Scholar

8 Kuwana M, Kaburaki J, Kitasato H, Kato M, Kawai S, Kawakami Y, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001;98:130-13910.1182/blood.V98.1.130Suche in Google Scholar

9 Eppley BL, Sidner RA, Sadove AM. Adequate preclinical testing of bioplastique injectable material? Plast Reconstr Surg 1992;89:157-15810.1097/00006534-199289010-00044Suche in Google Scholar

10 Ware RE, Howard TA. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood 1993;82:2137-214210.1182/blood.V82.7.2137.2137Suche in Google Scholar

11 Shimomura T, Fujimura K, Takafuta T, Fujii T, Katsutani S, Noda M, et al. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura. Br J Haematol 1996;95:732-73710.1046/j.1365-2141.1996.d01-1967.xSuche in Google Scholar PubMed

12 Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-425410.1182/blood.V87.10.4245.bloodjournal87104245Suche in Google Scholar

13 Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007;27:557-56210.1007/s10875-007-9111-1Suche in Google Scholar PubMed

14 Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 2009;94:1326-132910.3324/haematol.2009.007823Suche in Google Scholar PubMed PubMed Central

15 Cao J, Chen C, Zeng L, Li L, Li X, Li Z, et al. Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. Clin Immunol 2011;141:121-12310.1016/j.clim.2011.05.003Suche in Google Scholar PubMed

16 Cao J, Chen C, Li L, Ling-yu Z, Zhen-yu L, Zhi-ling Y, et al. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J Clin Immunol 2012;32:523-529 10.1007/s10875-012-9649-4Suche in Google Scholar PubMed

17 Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007;79:310-31610.1111/j.1600-0609.2007.00917.xSuche in Google Scholar PubMed

18 Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007;78:139-14310.1111/j.1600-0609.2006.00780.xSuche in Google Scholar PubMed

19 Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-112410.1038/nm921Suche in Google Scholar PubMed

20 Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006;76:427-43110.1111/j.1600-0609.2005.00622.xSuche in Google Scholar PubMed

21 Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93:1428-143010.3324/haematol.12889.Suche in Google Scholar

22 Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013;2013:276-28210.1182/asheducation-2013.1.276Suche in Google Scholar

23 Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost 2014;12:497-50410.1111/jth.12524Suche in Google Scholar

24 Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012;87:206-20810.1002/ajh.22211Suche in Google Scholar

25 Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-3310.7326/0003-4819-146-1-200701020-00006Suche in Google Scholar

26 Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-599510.1182/blood-2011-11-393975Suche in Google Scholar

27 Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-224710.1056/NEJMoa073275Suche in Google Scholar

28 Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-64810.1016/S0140-6736(09)60402-5Suche in Google Scholar

29 Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-168110.1056/NEJMoa054626Suche in Google Scholar

30 Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-40310.1016/S0140-6736(08)60203-2Suche in Google Scholar

31 Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol 2012;96:222-22810.1007/s12185-012-1124-8Suche in Google Scholar PubMed

32 Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755-276210.1182/blood-2009-07-229815Suche in Google Scholar PubMed

33 Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013;121:1976-198110.1182/blood-2012-09-455691Suche in Google Scholar PubMed

34 Cui ZG, Liu XG, Qin P, Hou M, Wu SL, Peng J, et al. Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia. Chin Med J (Engl) 2013;126:4145-414810.3760/cma.j.issn.0366-6999.20131116Suche in Google Scholar

35 Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood 2015;125:1541-154710.1182/blood-2014-06-581868Suche in Google Scholar PubMed PubMed Central

36 Leven E, Miller A, Cooper B, Bussel JB. Cyclosporine-Romiplostim-IVIG Combination Therapy in Refractory ITP, Blood 2012; abstract 109510.1182/blood.V120.21.1095.1095Suche in Google Scholar

37 Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009;114:5362-536710.1182/blood-2009-05-217513Suche in Google Scholar PubMed

38 Zhu XJ, Shi Y, Sun JZ, Shan NN, Peng J, Guo CS, et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009;29:603-61010.1007/s10875-009-9303-ySuche in Google Scholar PubMed

39 Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007;136:309-31410.1111/j.1365-2141.2006.06431.xSuche in Google Scholar PubMed

40 Semple JW. ITP has elevated BAFF expression. Blood 2009;114:5248-524910.1182/blood-2009-10-247536Suche in Google Scholar PubMed

41 Yu HM, Liu YF, Hou M. BAFF–an essential survival factor for B cells: Links to genesis of ITP and may be of therapeutic target. Med Hypotheses 2008;70:40-4210.1016/j.mehy.2007.05.005Suche in Google Scholar PubMed

Received: 2015-5-12

Accepted: 2016-2-21

Published Online: 2016-4-18

Published in Print: 2016-1-1

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.